Top Back to top

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Chronic Malignancies Working Party (CMWP)
Type d'étude:
Numéro de l'étude:
42205674
Type de traitement à base de cellules souches:
Allogeneic
Maladies:
Myelodysplastic (MDS) or MDS/MPN
Titre court:
 
Objectif principal:
To evaluate the impact of additional adverse cytogenetic abnormalities on relapse-free survival after allo-SCT in MDS with very poor risk cytogenetics.
Principaux critères d'inclusion:
 MDS
 CR1, CR2 and beyond
 Age >= 18
 MDS with more than 3 cytogenetic abnormalities at diagnosis
 First allogeneic SCT
 Allogeneic SCT from matched family or matched unrelated donor between 2000 and 2016
Pays:
 
Investigateur principal:
Xavier Poiré
Coordinateur EBMT de l'étude:
Linda Koster
E-mail du coordinateur de l'étude:
cmwpebmt@lumc.nl